Chimerix, Inc. (NASDAQ:CMRX) Shares Sold by Yakira Capital Management Inc.

Yakira Capital Management Inc. reduced its holdings in shares of Chimerix, Inc. (NASDAQ:CMRX) by 79.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 103,489 shares of the biopharmaceutical company’s stock after selling 404,900 shares during the quarter. Yakira Capital Management Inc. owned 0.12% of Chimerix worth $360,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Stoneridge Investment Partners LLC boosted its stake in Chimerix by 22.5% during the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after acquiring an additional 8,134 shares during the last quarter. Bender Robert & Associates acquired a new stake in shares of Chimerix in the 4th quarter valued at about $37,000. Charles Schwab Investment Management Inc. bought a new position in shares of Chimerix during the fourth quarter worth about $183,000. Palumbo Wealth Management LLC acquired a new position in Chimerix in the fourth quarter worth about $221,000. Finally, Valeo Financial Advisors LLC increased its holdings in Chimerix by 78.8% in the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock valued at $509,000 after buying an additional 64,420 shares during the last quarter. Institutional investors and hedge funds own 45.42% of the company’s stock.

Insider Buying and Selling at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total value of $33,312.40. Following the sale, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. This trade represents a 1.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 20,760 shares of company stock valued at $91,175 in the last ninety days. Company insiders own 13.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on CMRX shares. Wedbush reaffirmed a “neutral” rating and set a $8.55 target price (up previously from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. HC Wainwright reissued a “neutral” rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a research report on Wednesday, March 5th. StockNews.com started coverage on shares of Chimerix in a report on Monday, March 31st. They issued a “hold” rating for the company. Finally, Jefferies Financial Group reissued a “hold” rating and set a $8.50 target price (down from $10.00) on shares of Chimerix in a report on Wednesday, March 5th.

Chimerix Stock Performance

Shares of NASDAQ CMRX opened at $8.53 on Friday. Chimerix, Inc. has a 12-month low of $0.75 and a 12-month high of $8.54. The company has a market cap of $800.15 million, a price-to-earnings ratio of -9.07 and a beta of -0.18. The stock’s 50 day simple moving average is $6.32 and its 200 day simple moving average is $3.37.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.01. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.31 million. As a group, equities analysts forecast that Chimerix, Inc. will post -0.99 earnings per share for the current fiscal year.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.